Famotidine's Possible Cutaneous Rash in COVID-19 Patients: An Adverse Effect Case Series.
COVID-19
SARS CoV-2
adverse effect
cutaneous lesions
famotidine
rash
red spot
Journal
Current drug safety
ISSN: 2212-3911
Titre abrégé: Curr Drug Saf
Pays: United Arab Emirates
ID NLM: 101270895
Informations de publication
Date de publication:
2022
2022
Historique:
received:
06
01
2021
revised:
21
06
2021
accepted:
29
08
2021
pubmed:
13
10
2021
medline:
30
7
2022
entrez:
12
10
2021
Statut:
ppublish
Résumé
Various cutaneous manifestations have been observed in patients with COVID-19 infection. However, the side effects on skin of the medications used for COVID-19, such as famotidine, have not been studied. This case series aims to present challenges in defining cutaneous manifestations of famotidine in the context of COVID-19. We identified patients from Imam Khomeini hospital complex who were admitted to the ward due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), were taking famotidine and having cutaneous rash. Clinical data were obtained through observation and intervention. We found 4 SARS-CoV-2 patients with cutaneous manifestations. The mean (±SD) age of the patients was 57±2 years, 3 patients were men, and their COVID-19 symptoms appeared 10±3 days before admission. The most common symptoms were cough and shortness of breath. All the patients were admitted for hypoxemic respiratory failure. Patients received famotidine for gastrointestinal prophylaxis, and all 4 patients developed Acral macular mountainous skin lesions in the upper and lower extremities, then we discontinued famotidine and lesions were recovered completely in all patients. These cases prompted us to inform clinicians about cutaneous complications of famotidine in COVID-19 patients.
Sections du résumé
BACKGROUND
BACKGROUND
Various cutaneous manifestations have been observed in patients with COVID-19 infection. However, the side effects on skin of the medications used for COVID-19, such as famotidine, have not been studied.
OBJECTIVE
OBJECTIVE
This case series aims to present challenges in defining cutaneous manifestations of famotidine in the context of COVID-19.
CASE PRESENTATION
METHODS
We identified patients from Imam Khomeini hospital complex who were admitted to the ward due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), were taking famotidine and having cutaneous rash. Clinical data were obtained through observation and intervention.
DISCUSSION
CONCLUSIONS
We found 4 SARS-CoV-2 patients with cutaneous manifestations. The mean (±SD) age of the patients was 57±2 years, 3 patients were men, and their COVID-19 symptoms appeared 10±3 days before admission. The most common symptoms were cough and shortness of breath. All the patients were admitted for hypoxemic respiratory failure. Patients received famotidine for gastrointestinal prophylaxis, and all 4 patients developed Acral macular mountainous skin lesions in the upper and lower extremities, then we discontinued famotidine and lesions were recovered completely in all patients.
CONCLUSION
CONCLUSIONS
These cases prompted us to inform clinicians about cutaneous complications of famotidine in COVID-19 patients.
Identifiants
pubmed: 34636306
pii: CDS-EPUB-118301
doi: 10.2174/1574886316666211005102711
doi:
Substances chimiques
Famotidine
5QZO15J2Z8
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
269-273Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.